US4851341A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Immunoaffinity purification system
Assignee: Sigma-Aldrich Co LLC
•
Filing: 1986-12-19
•
Granted: 1989-07-25
•
Expires: 2006-12-19
Abstract
Abstract A process is disclosed for purifying a recombinant fusion protein having an N-terminal identification sequence comprising multiple anionic amino acid residues, comprising forming a complex of the protein with a divalent cation dependent monoclonal antibody specific for the sequence, isolating the complex, and dissociating antibody and protein by selectively depleting the concentration of divalent cations in contact with the complex. A particular calcium-dependent monoclonal antibody, 4E11, is useful in an embodiment of the process which employs the identification peptide DYKDDDDK.
Inventors
- 👤 Thomas P. Hopp
- 👤 Kathryn S. Prickett
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:28
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/62; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/53; C07K14/535; C07K14/54; C07K14/545; C07K16/00; C07K16/18; C07K16/24; C07K16/243; C07K16/244; C07K16/44; C07K7/00; C07K7/04; C07K7/06; C07K2317/00; C07K2317/30; C07K2317/34; C07K2319/00; C07K2319/01; C07K2319/036; C07K2319/40; C07K2319/43; C07K2319/50; C07K2319/70; C07K2319/74; C07K2319/75; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/14; Y10S930/145; Y10S930/30
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
81 words
A process for purifying a recombinant fusion protein having a terminal peptide identification sequence comprising selected multiple anionic amino acid residues, comprising forming a complex of the protein with a divalent cation dependent monoclonal antibody specific for the sequence in the presence of a divalent cation concentration sufficient to enable formation of said complex, isolating the complex, dissociating antibody and protein by selectively depleting the concentration of divalent cations in contact with the complex and separating said protein from said antibody.
Claim 2
Dependent Claim
81 words
A process for purifying a recombinant fusion protein having a terminal peptide identification sequence comprising selected multiple anionic amino acid residues, comprising forming a complex of the protein with a divalent cation dependent monoclonal antibody specific for the sequence in the presence of a divalent cation concentration sufficient to enable formation of said complex, isolating the complex, dissociating antibody and protein by selectively depleting the concentration of divalent cations in contact with the complex and separating said protein from said antibody.
Claim 3
Dependent Claim
21 words
A process according to claim 1, wherein the identification peptide comprises from 3 to 6 aspartic acid or glutamic acid residues.
Claim 4
Dependent Claim
44 words
A process according to claim 2, wherein the divalent cation is selected from the group consisting of Ca ++ , Mg ++ , Mn ++ , Cu ++ , Ni ++ , Zn ++ , Cd ++ , Ba ++ and Sr ++ .
Claim 5
Dependent Claim
19 words
A process according to claim 3, wherein antibody and protein are dissociated by depleting cations with a chelating agent.
Claim 6
Dependent Claim
14 words
A process according to claim 4, wherein the chelating agent is EDTA or EGTA.
Claim 7
Dependent Claim
12 words
A process according to claim 5, wherein the chelating agent is EDTA.
Claim 8
Dependent Claim
14 words
A process according to claim 6, wherein the divalent cation is Ca ++ .
Claim 9
Dependent Claim
13 words
A process according to claim 7, wherein the identification sequence is N-terminal DYKDDDDK.
Claim 10
Dependent Claim
21 words
A process according to claim 8, wherein the monoclonal antibody is that secreted by the murine hybridoma 4E11 (ATCC HB 9259).
Claim 11
Dependent Claim
110 words
A process for producing a fusion protein comprising a polypeptide encoded by a structural gene inserted in a prokaryotic or eukaryotic expression vector, comprising inserting adjacent to the structural gene a DNA sequence encoding a terminal identification peptide comprising selected multiple anionic amino acid residues; expressing the structural gene as a fusion protein comprising the identification peptide covalently linked to the polypeptide; separating the fusion protein from contaminants by forming a complex of the protein with a divalent cation-dependent monoclonal antibody specific for the identification peptide wherein said monoclonal antibody is capable of binding said peptide only in the presence of divalent cations and separating said protein from said antibody.
Claim 12
Dependent Claim
110 words
A process for producing a fusion protein comprising a polypeptide encoded by a structural gene inserted in a prokaryotic or eukaryotic expression vector, comprising inserting adjacent to the structural gene a DNA sequence encoding a terminal identification peptide comprising selected multiple anionic amino acid residues; expressing the structural gene as a fusion protein comprising the identification peptide covalently linked to the polypeptide; separating the fusion protein from contaminants by forming a complex of the protein with a divalent cation-dependent monoclonal antibody specific for the identification peptide wherein said monoclonal antibody is capable of binding said peptide only in the presence of divalent cations and separating said protein from said antibody.
Claim 13
Dependent Claim
21 words
A process according to claim 10, wherein the identification peptide comprises from 3 to 6 aspartic acid or glutamic acid residues.
Claim 14
Dependent Claim
19 words
A process according to claim 11, wherein antibody and protein are dissociated by depleting cations with a chelating agent.
Claim 15
Dependent Claim
12 words
A process according to claim 12, wherein the chelating agent is EDTA.
Claim 16
Dependent Claim
14 words
A process according to claim 13, wherein the divalent cation is Ca ++ .
Claim 17
Dependent Claim
13 words
A process according to claim 14, wherein the identification sequence is N-terminal DYKDDDDK.
Claim 18
Dependent Claim
21 words
A process according to claim 15, wherein the monoclonal antibody is that secreted by the murine hybridoma 4E11 (ATCC HB 9259).
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-07-24 | 1993-01-23 | 1993-07-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-07-24 | 1997-01-23 | 1997-07-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-07-24 | 2001-01-23 | 2001-07-25 | $7700.00 | Window Closed / Lapsed |